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Summary 
DW/J dwarf mice have a defect in their anterior pituitary and are deficient in growth hormone 
(GH) and prolactin (PRL). These mice have been demonstrated previously to have a deficiency 
in CD4/CD8 double-positive thymocytes, which could be corrected by treatment of these mice 
with recombinant human GH. Since PRL has been implicated in T  cell function and human 
GH can interact with the PILL receptor,  DW/J dwarf mice were treated with either ovine GH 
(ovGH) (20/zg/d) or ovine PILL (OVPRL) (20/zg/d). The ovine hormones can only bind their 
own specific receptors in the mouse. After several weeks of treatment, it was found that these 
two hormones produced markedly contrasting effects on T cells. Phenotypic analysis of the lymphoid 
organs was performed by flow cytometry and the functional capability of the peripheral T cells 
was assessed by immunizing the mice and determining the extent of antigen-specific proliferation 
of T cells obtained from the draining lymph nodes or by determining splenic mitogen responses. 
The results indicated that ovGH administration to dwarf mice resulted in significant  increases 
in thymic cellularity yet had little effect on peripheral T cell responses. In contrast, the administration 
of ovPRL resulted in a further decrease in thymic cellularity when compared with untreated 
dwarf mice. No thymic effects of either ovGH or ovPRL administration were detected on the 
normal +/? counterparts. However, ovPRL administration resulted in a significant increase in 
the number and function of antigen-specific  peripheral T  cells in both immunized dwarf and 
+/? mice. The adjuvant effects of PRL occurred even though the mice also received complete 
Freund's adjuvant. These results suggest that neuroendocrine hormones may act in concert in 
T cell development. GH appears to promote thymocyte  proliferation, while PILL appears to decrease 
thymus size and yet augment the number and function of antigen-specific T cells in the periphery. 
N 
'euroendocrine hormones have long been thought to play 
a role in T cell development and function (1). In par- 
ticular,  growth hormone (GH) 1 has been postulated to be 
a mediator important in thymic development (1, 2). Studies 
using neuroendocrine hormone-deficient dwarf mice have 
proven especially useful in dissecting the potential role of these 
hormones in T  cell development (3, 4). DW/J dwarf mice 
have a defect in their anterior pituitary and, as a result, are 
deficient in the production of GH, prolactin (PRL), and other 
neuroendocrine mediators  (4).  Aside  from  the  expected 
deficiencies in growth, these mice have also been reported 
to have deficiencies in T  cell development and function (4, 
5). We have recently found that these mice have deficiencies 
in CD4 +  CD8 + double-positive cells within their thymi and 
1Abbreviations used in thispat,  er: GH, growth hormone; LNC, lymph node 
cells; ov, ovine; PILL, prolactin; rh, recombinant human. 
that treatment of these mice with either recombinant human 
(rh)GH or ovine (ov)GH could restore this T cell progenitor 
population within the thymus (6).  Treatment with rhGH 
also resulted in an increase in thymic size and a modest in- 
crease in peripheral T cell function in these mice (6). These 
results suggested that GH can exert thymopoietic effects after 
in vivo administration and may be important for the main- 
tenance of thymic function. However,  rhGH can also bind 
the PILL receptor and can mediate effects associated  with signal 
transduction through the PRL receptor (7). PRL has also 
been implicated in T cell development and has been suggested 
to be important for T  cell function (8, 9).  To address the 
role of PILL on T cell development, DW/J mice were given 
either ovGH, which cannot bind the murine PRL receptor 
(7), or ovPRL alone. We report here that these two closely 
related hormones in fact yield contrasting effects on T cells 
in dwarf mice. ovGH appears to act early during T cell de- 
velopment within the thymus whereas ovPRL appears to affect 
mature T cell function in the periphery. These results sug- 
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on T cells and may be of possible use in specific clinical set- 
tings where thymic or peripheral T  cell stimulation might 
be indicated. 
Materials and Methods 
Mice.  DW/J dw/dw mice and their control heterozygous litter- 
mates, consisting ofdw/+  and +/+ (abbreviated +/?), were pur- 
chased from The Jackson Laboratory (Bar Harbor, ME). The mice 
were not used until 8-9 wk of age and were kept under specific 
pathogen-free conditions until use. The mice were housed with 
control littermates, had food pellets placed on the bottom of the 
cages, and had water and food intake monitored. The mice were 
periodically tested for exposure to common routine pathogens be- 
fore entering the colony at the National Cancer Institute, Frederick 
Cancer Research  and Development  Center (NCI-FCRDC) and were 
necropsied upon day of death to determine evidence for bacterial 
infection. 
Antibodies and Flow Cytoraetric Analysis.  Thymocytes, spleno- 
cytes, and lymph node cells (LNC) (brachial, inguinal, axillary,  and 
mesenteric) were suspended in HBSS and incubated with the ap- 
propriate fluorochrome-conjugated  antibodies. The single-cell  sus- 
pensions were first counted using a cell  counter (Coulter Electronics, 
Hialeah, FL), and a Student's t test was used to determine if the 
organ cellularities  were significantly  different. The cells were then 
fixed in 1% paraformaldehyde  and anaJyzed  using an EPICS flow 
cytometer (Coulter Electronics). Each two-color fluorescence  study 
included controls of normal rat serum (NR-FITC and NR-PE). 
The primary antibodies were: anti-CD3-FITC, anti-CD8 (Lyt-2- 
FITC), and anti-CD4 (L3T4-biotinylated), which were purchased 
from Becton Dickinson & Co. (Mountain View, CA). All experi- 
ments were performed three to four times and had two to four 
mice per group with a representative mouse being shown. 
Treatment with ovGH or ovPRL.  Mice  in some  groups received 
20 #g of ovGH or 20/~g of ovPRL (both provided by a hormone 
repository run by the National Institute of  Diabetes and Digestive 
and Kidney Diseases, the Center for Population Research of the 
National Institute of Child Health and Human Development, the 
Agricultural Research Service of the U.S. Department of Agricul- 
ture (Bethesda, MD), and the University of Maryland School of 
Medicine, Baltimore, MD) resuspended  in 0.2 ml PBS and injected 
intraperitoneally every  day for 8 wk or until the mice were assayed. 
The percent of contamination of the hormones with each other 
was 0.03%. Control mice received 0.2 ml PBS daily. Mice were 
weighed weekly until termination of study. 
Antigen-specific T  Cell Proliferation and Splenic Mitogen Assays. 
Mice were immunized at the base of the tail with 100/~g of KLH 
(Calbiochem-Behring  Corp., LaJolla, CA) in CFA (Mycobacterium 
tuberculosis strain H37Ra; Difco Laboratories,  Detroit, MI). 7 d later 
the two draining lymph nodes (inguinal) from three to five mice 
were removed and single-cell  suspensions were made. In some ex- 
periments, the B cells were removed by incubating the LNC sus- 
pension on 24-well duster plates (Costar, Cambridge, MA) coated 
with goat anti-mouse Ig (a kind gift from Dr. James Kenny, Pro- 
gram Resources, Inc./DynCorp, NCI-FCRDC, Frederick, MD) 
for 1 h at 37~  at a concentration of 106 ceUs/ml. The nonad- 
herent cells (5  x  10  s) were then cultured in R.PMI 1640 sup- 
plemented with 0.5%  fresh syngeneic serum and 50/~M 2-ME 
(Sigma Chemical Co., St. Louis, MO) in flat-bottomed microtiter 
wells (Costar). KLH (100 ~g/ml) was then added to cultures. 4 d 
later proliferation was assayed  by pulsing with 1 #Ci (3.7  x  104 
becquerels) of [3H]thymidine (6.7 Ci/mmol) (New England Nu- 
clear, Boston, MA) for 4 h and harvesting with a MASH II ap- 
paratus (Microbiological  Associates, Bethesda, MD). In the splenic 
mitogen assay, splenocytes  were obtained, counted, and cultured 
at 10  s in 0.2 ml of the same medium described above in the LNC 
proliferation assay along with Con A (Sigma Chemical Co.) at a 
concentration of 5 #g/ml. After 2 d of incubation at 37~  the 
cultures were pulsed for 3 h with [3H]Tdr, harvested, and thymi- 
dine incorporation  was quantitated as described  in the LNC prolifer- 
ation assay. All data are presented as means with standard devia- 
tion.  A Student's t test was performed to determine statistical 
differences with p values <0.05 being considered significant. 
Results 
Administration  of ovGH or ovPRL to Dwarf Mice Yields Op- 
posite Effects on Thymic Cellularity.  We have previously de- 
termined that rhGH exerted thymopoietic effects after in vivo 
administration to dwarf mice (6). We then wanted to deter- 
mine if ovPRL also could exert effects on the dwarf thymus 
after in vivo administration in these mice since hGH can also 
bind the PRL receptor (7).  Dwarf mice and their control 
+/? littermates were given 20 #g of either ovGH or ovPRL 
every day for 3 wk since the ovine hormones only can bind 
their respective receptors in the mouse (7). At this dose range, 
modest but not always statistically significant increases in 
growth occurred in the dwarf mice that were treated with 
ovGH (data not shown). No effects on growth were seen 
in any of the + / ? littermates or dw/dw mice receiving ovPRL. 
Upon analysis, the thymi from untreated dwarf mice were 
markedly hypocellular, as has been previously described  (3, 
4,  6).  Furthermore, administration of ovGH to these mice 
resulted in a significant (p <0.001)  increase  in thymic cel- 
lularity (Fig.  1). In marked contrast, the administration of 
ovPRL resulted in a significantly (p <0.001) decreased thymic 
cellularity in dwarf mice. No effect of ovGH or ovPRL was 
detected on the thymic cellularity of +/? control littermates 
(data not shown). Phenotypic analysis of the dwarf thymo- 
cytes was then performed. Untreated dwarf mice again dis- 
played a modest decrease in CD4/CD8 double-positive thymo- 
cytes (Fig. 2 a), as has been previously reported (6, 10). The 
extent of the double-positive T cell deficiency is quite vari- 
able and may be related to the increased susceptibility of these 
mice to stress (6).  However, treatment of these mice with 
ovGH resulted in a slight increase in double-positive ceils (Fig. 
2 b), which is also in agreement with previous reports (6). 
Interestingly, the administration of ovPRL resulted in fur- 
ther reduction of the double-positive cells, the residual being 
somewhat enriched for mature CD4 and CD8 single-positive 
thymocytes, particularly CD4 + cells (Fig.  2 c).  It appears 
therefore that ovGH can mediate increases in thymic cellularity 
and results in increases in double-positive cells, whereas ovPRL 
produces the opposite effects and results in decreases in both 
cellularity and the percentage of double-positive thymocytes 
in neuroendocrine-deficient dwarf mice. No effect of ovPRL 
or ovGH administration was detected on the thymic progen- 
itor distribution of the normal control littermates (data not 
shown). Thus, the previously reported thymopoietic effects 
of  rhGH in dwarf mice (6) appear to be mediated by the ability 
of human GH to bind the GH receptor and not the PKL 
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Figure  1.  Thymic cellularity in dwarf mice after ovGH or ovPRL ad- 
ministration. Dwarf mice were treated with either 20/zg ovGH or 20 
/zg ovPRL daily for 8 wk as described in Materials and Methods.  The 
data represent four experiments with three to four mice per group. Treat- 
ment with ovGH resulted in a significant (*p <0.001) increase in thymic 
cellularity when compared with untreated controls. Treatment with ovPRL 
resulted in a significant (* *p <0.001) decrease in thymic cellularity when 
compared with untreated controls. 
receptor since the ovine hormones produce contrasting effects 
on thymic cellularity in neuroendocrine~defident dwarf mice. 
Administration of  ovPRL Increases Peripheral T Cell Function 
in Both dw/dw and +/? Mice.  We then wanted to assess pe- 
ripheral T cell content and function in mice as a consequence 
of either ovGH or ovPRL administration.  There was no 
significant effect of ovGH or ovPRL administration on lymph 
node cellularity in unimmunized dwarf or + / ? control mice 
(Fig. 3 A). Additionally, phenotypic analysis of the lymph 
nodes indicated that ovGH or ovP1LL did not significantly 
alter the percentages of CD4 or CD8 cells in the dwarf mice 
(Fig. 2, d-J). CD4/CD8 double-positive T cells, which have 
previously been reported to occur in the periphery of these 
mice to a variable extent (6), were nonexistent in the lymph 
nodes of dwarf mice treated with ovPRL, while the lymph 
nodes of control and ovGH-treated mice did contain a small 
percentage of double-positive T cells (2-3% shown) (Fig. 2). 
To ascertain the functional capability of the peripheral T 
cells in hormone-treated  mice, we immunized the mice with 
KLH in CFA and 7 d later the draining lymph nodes were 
removed. The cells were then rechallenged with KLH in vitro 
and the extent of antigen-specific  proliferation was determined. 
In some experiments lymph node B cells were removed be- 
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Figure 2.  Phenotype of thymocytes and pooled LNC of dw/dw mice after treatment with ovGH or ovPRL. CD4 and CD8 staining was determined 
through flow cytometry and described in Materials and Methods.  The data display a representative mouse selected from three to four experiments 
each with three to four mice per group. (a) Thymocytes from control animals; (b) thymocytes from ovGH-treated animals; (c) thymocytes from ovPRL- 
treated mice; (d) LNC from control animals (to include axillary, inguinal, mesenteric, and brachial lymph nodes); (e) LNC from ovGH-treated animals; 
(/) LNC from ovPtLbtreated  animals. 
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Figure 3.  LNC cellularity in im- 
munized and unimmunized dw/dw 
mice after treatment with ovGH or 
ovPRL. Mice were treated  as de- 
scribed in Materials and Methods. 
(A) Total LNC cellularity (inguinal, 
axillary, mesentetic, and brachial) in 
dw/dw mice after ovPRL or ovGH 
administration.  (B) Cellularity of 
draining  (two  inguinal)  LNC  in 
dw/dw mice that were immunized 
with KLH in CFA and treated with 
ovGH or ovPRL. There was an av- 
erage  of  three  to  four  mice  per 
group. 
fore culture to demonstrate that the proliferative responses 
were indeed T cell dependent. There were no significant differ- 
ences in the proliferative responses between whole LNC and 
B cell-depleted LNC (data not shown). We have determined 
previously that 3-4-mo-old dw/dw  mice do have functional 
T cells in their periphery, although at lower levels than their 
+/? littermates (6).  The mice in these experiments were 
treated with ovGH or ovPRL for 2 mo and were 4 mo old 
at the time of assay. LNC from control dw/dw mice that were 
treated with saline injections before immunization displayed 
a modest proliferative response after being rechallenged with 
KLH (Table 1). Interestingly, ovGH did not significantly  en- 
hance the T cell responses in either dw/dw or  +/? mice and 
the lymph node cellularity did not increase significantly (Table 
1; Fig. 3 B). The increase in the extent of proliferation in 
the  +/? recipients treated with ovPRL, while statistically 
significant in this experiment, was variable  in others (data 
not shown). However, the results demonstrate that both im- 
munized dw/dw and +/? mice responded to ovPRL adminis- 
tration with significantly (p < 0.001) higher LNC yields con- 
taining antigen-specific  cells compared with either control 
or ovGH-treated mice (Table 1; Fig. 3 B). It is of particular 
interest that even the immunized +/? littermates responded 
to ovPlLL. 
To determine if the increase in peripheral T  cell content 
in response  to PILL treatment was due to an expansion of 
antigen-specific cells in the LNC or if  ovPRL treatment caused 
an expansion of all peripheral T cells, splenic T cell mitogen 
responses were determined. The data demonstrate that splenic 
cellularity and mitogen-induced proliferative responses were 
not affected by ovPRL treatment in the immunized recipients 
(Table 2). Increases in splenic cellularity and total T cell number 
Table  1,  Antigen-specific  Responses of Peripheral T  Cells in DW/J dw/dw and  +/? Mice 
[3H]Thymidine  incorporation 
Strain  Treatment*  Cell yield*  - KLH  + KLH 
x 10'  cpm 
+/?  -  3.9  +_  2.9  4,495  _+  502s  24,796  _+  993 
+/?  ovGH  1.7  _+  1.0  2,713  +  255  22,167  _+  1,943 
+/?  ovPRL  13.3  _+  3.711  3,303  +  430  31,683  _+  1,8931 
dw/dw  -  1.1  +  0.2  995  _+  141  2,240  _+  225 
dw/dw  ovGH  0.9  _+  0.2  808  _+  161  1,323  _+  1,121 
clw/clw  ovPRL  2.1  _+  0.2 II  1,871  _+  474  7,032  _+  1,463 
* Mice were injected  with 20 #g ovGH or ovPRL intraperitonally  every day starting at 8 wk of age.  Mice were analyzed  8 wk later. 
* Average value from two inguinal LNC per mouse with three mice per group and with the proliferation  assay performed as described in Materials 
and  Methods. 
S Data presented  as means with standard  deviation. 
II LNC cell yield significantly  (p <0.001)  greater than mice not treated  with ovPRL. 
￿82  Values  significantly  (p <0.001)  greater  than mice not treated  with ovPRL. 
234  Neuroendocrine Hormones and T  Cell Function Table  2.  Effect  of ovGH or ovPgL Administration of Splenic Mitogen Responsiveness 
Strain  Treatment"  Cells/spleent  -  Con A  + Con A 
x 106  cpm 
dw/dw  -  5.2  •  1.5  1,436  •  255s  15,104  _+  1,223 
dw/dw  ovGH  15.1  •  4.1  1,620  •  414  9,752  +_  1,163 
dw/dw  ovPRL  6.6  •  4.3  1,197  +_ 555  10,794  +_ 4,217 
+/?  -  61.0  •  12.4  2,629  •  466  10,453  _+ 638 
+/?  ovGH  58.8  _+ 2.8  1,811  +  416  9,786  •  2,133 
+/?  ovPRL  78.9  +  9.8  1,481  _+ 625  9,245  _+  1,536 
Mitogen assay performed as described in Materials and Methods. 
" Mice received either 20 #g of ovPRL or 20 #g of ovGH intraperitoneaUy every day for 8 wk. 
Average splenic cellularity of three mice per group. 
s Data are presented as means with standard deviation. 
did occur after ovGH treatment however. The conclusion that 
ovPRL promotes the proliferation of antigen-specific T cells 
during a primary immune response is further supported by 
data  demonstrating  that  PILL treatment  had  no effect on 
lymph node cellularity in unprimed mice (Fig. 2 a). Thus, 
it appears that ovPRL exerts a strong adjuvant effect on the 
antigen-specific priming of peripheral T cells in mice. Addi- 
tionally, it appears that, while exerting significant thymopoietic 
effects in dwarf mice after in vivo administration,  ovGH does 
not directly influence mature antigen-specific T cell function 
in the periphery. In marked contrast, administration of ovPRL 
produced the opposite effects, in which thymic size actually 
decreased and there was an increase in antigen-specific pe- 
ripheral T cell number after immunization. Additionally,  while 
the thymic effects of these hormones occurred only in dw/dw 
mice, the effects of ovPRL on peripheral T cell function oc- 
curred  in both immunized  dw/dw and normal  +/?  mice. 
Discussion 
The results presented here demonstrate that the neuroen- 
docrine hormones GH and PRL can exert significant and di- 
verse effects on T  cell development and function in DW/J 
dwarf mice. GH appears to act early in T  cell development 
as a thymopoietic agent, which results in an increase in thymic 
cellularity and restoration of CD4/CD8 double-positive pro- 
genitor cells within  the thymi of dwarf mice.  In contrast, 
PILL does not exhibit thymopoietic activity and in fact reduces 
the  number  of thymocytes in vivo.  However, PILL exerts 
significant effects on increasing antigen-specific peripheral T 
cell proliferation in both dwarf and normal mice. While there 
is considerable evidence to demonstrate the proliferative  effects 
of PRL on T  cells  in vitro (8, 9),  the data presented here 
extend these findings and suggest that PILL can be used as 
an adjuvant in vivo. It is important to note that the adjuvant 
effects of ovPRL were detected in mice that were also given 
the adjuvant CFA. Since rhGH can bind both the GH and 
PRL receptor and mediate functions due to both of these 
binding activities (7), it may be of use clinically to promote 
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T  cell development  since both the thymopoietic effects of 
GH and the peripheral T cell effects of PRL may be obtained. 
However, it has been recently reported that human T  lym- 
phocytes can synthesize hPRL (9). Murine T  cells do not. 
It will be of interest to evaluate the effects of exogenous hPRL 
and hGH  on human  T  cell function. 
The mechanism underlying the thymopoietic effects of GH 
in dwarf mice is currently not known.  We have previously 
shown  that  GH  exerts  significant  hematopoietic  growth- 
promoting effects in vivo (11, 12), and GH may cause an in- 
crease in the production of T cell progenitors from the bone 
marrow. Alternatively,  GH may influence the thymus directly. 
We are currently examining  the effect of ovGH on thymic 
stromal cells  and thymic architecture. 
The in vivo effects of PRL administration include decreasing 
thymic cellularity and augmenting  antigen-specific periph- 
eral T cell expansion in the lymph nodes. It has been previ- 
ously demonstrated that PRL can augment T cell prolifera- 
tion in vitro (9). It may be that PRL also plays a role in thymic 
selection by providing a similar activating signal. Due to the 
critical stage in thymic selection in which activation can re- 
sult in apoptosis, an activating signal provided by PRL may 
be detrimental for T  progenitor survival while optimal for 
peripheral mature T cell activation and expansion. However, 
the effects of ovPRL may also be indirect  since it has been 
recently reported  that  thymic epithelial  cells express PILL 
receptors (13). Indeed, preliminary results indicate that ovPRL 
does not induce apoptosis of thymocyte suspensions in vitro 
(our unpublished observations). However, it is also impor- 
tant to note that the thymic effects of the two hormones only 
occurred in the dwarf mice. It may be that prolonged neu- 
roendocrine  hormone  deprivation  predisposes  the  dwarf 
thymocytes to the effects of ovGH or ovPRL administration. 
DW/J dwarf mice congenitally lack the capability to pro- 
duce GH and PILL as well as other neuroendocrine hormones. 
However, it has been established that maternal milk can pro- 
vide some protective effects as the mice do not appear to dem- 
onstrate significant immunological and hematopoietic deficien- 
des until  after weaning  (4,  10). PILL has been associated previously with autoimmunity 
(14). It has been shown recently that PRL accelerates autoim- 
mune disease in autoimmune-prone mice, and treatment of 
these mice with drugs that  inhibit  PRL release  delays the 
onset of the disease (15).  As we have found that  PRL ad- 
ministration  increases  peripheral T  cell function, it may be 
that PILL allows for an expansion of autoimmune T cells in 
the periphery. Experiments are currently underway to assess 
Vfl gene usage of the T  calls in mice after PRL administra- 
tion. PRL may also act indirectly and affect APC in the pe- 
riphery. 
Thus, through studies on neuroendocrine hormone-deficient 
dwarf mice, it appears that GH and PILL are capable of ex- 
erting significant effects on T  cell development.  Although 
these two hormones are dosdy related, they produce diverse 
effects upon in vivo administration.  In light of the minimal 
toxicities associated with their in vivo administration,  these 
hormones and their antagonists  may be therapeutic agents 
able to regulate T cell development and activation clinically. 
We acknowledge the superb technical assistance of Ms. Christie  Harrison,  Ms. Kelli Taylor, Ms. Louise 
Finch, and the Flow Cytometry Laboratory. The secretarial services of Ms. Terry PhiUips are also greatly 
appreciated. The assistance of Dr. Mark Smith in the performance of the apoptosis studies is greatly ap- 
preciated. We are indebted  to Dr.  Keith Kelley for stimulating  discussions and for criticaUy reviewing 
the manuscript. 
Address correspondence to WiUiam  J. Murphy, Biological Response Modifiers Program, Division of Cancer 
Treatment, NCI-Frederick Cancer Research and Development Center, Building 567, Room 141, Frederick, 
MD 21702-1201. 
gecei~d for publkation  12January  1993 and in revised  form 34 March 1993. 
References 
1.  KeUey,  K.W. 1989. Commentary.  Growth hormone, lympho- 
cytes and macrophages. Biochem. Pharmacol. 38:705. 
2.  Kelley, K.W., S. Brief, H.J. Westly, J. Novakofski, P.J. Bechtel, 
J. Simon, and E.B. Walker. 1986. GH3, pituitary adenoma cells 
can reverse thymic aging in rats. Proc. Natl. Acad. Sci. USA. 
83:5663. 
3.  Duquesnoy,  R.J.  1972. Immunodeficiency  of the  thymus- 
dependent  system of the Ames  dwarf mouse, f  Immunol. 
108:1578. 
4.  Duquesnoy, K.J., and G.M. Pedersen. 1981. Immunologic and 
hematologic deficiencies of the hypopituitary dwarf mouse. In 
Immunologic Defects in Laboratory  Animals, vol.  1, M.E. 
Gershwin and B. Merchant,  editors. Plenum Publishing Cor- 
poration,  New York. 309-324. 
5.  Fabris, N., W. Pierpaoli, and E. Sorkin. 1971. Hormones and 
the immunological  capacity III.  The immunodeficiency dis- 
ease of the hypopituitary  SneU-Bagg dwarf mouse. Clin. Exp. 
Immunol. 9:209. 
6.  Murphy, W.J., S.K. Durum, and D.L. Longo. 1992. The role 
neuroendocrine  hormones  in  murine  T-cell development: 
growth hormone exerts thymopoiedc effects  in vivo.J. Immunol. 
149:3851. 
7.  KUI, H., J.Y. Djeu, G.A. Evans, P.A. Kelly, and W.L. Farrar. 
1992. Prolactin receptor triggering.  Evidence for rapid tyro- 
sine kinase activation, f  Biol. Chem. 267:24076. 
8.  Clevenger, C.V., S.W. Altmann,  and M.B. Prystowsky. 1991. 
Requirement of nuclear prolactin for interleukin-2-stimulated 
proliferation of T lymphocytes. Science (Wash. DC). 253:77. 
9.  Sabharwal, P.,  R.  Glaser, W. Lafuse, S. Varma, Q.  Lin,  S. 
Arkins,  R.  Kooijman,  L.  Kutz,  K.W. Kdley,  and  W.B. 
Malarkey. 1992. Prohctin synthesized and secreted by human 
peripheral blood mononuclear cells: an autocrine growth factor 
for lymphoproliferation.  Pro~ Natl. Acad. Sci. USA. 89:7713. 
10.  Cross, R.J., J.S. Bryson, and T.L. Roszman.  1992. Immuno- 
logic disparity in the hypopituitary dwarf mouse.J. Immunol. 
148:1347. 
11.  Murphy, W.J.,  S.K. Durum, M.R. Anver, and D.L. Longo. 
1992. Immunologic and hematologic effects of neuroendocrine 
hormones: studies on DW/J dwarf mice.f Immunol. 148:3799. 
12.  Murphy,  W.J.,  G. Tsarfaty, and D.L. Longo.  1992. Growth 
hormone exerts hematopoietic growth-promoting effects  in vivo 
and  partially  counteracts  the  myelosuppressive effects of 
azidothymidine. Blood. 80:1443. 
13.  Dardenne,  M., P.A. Kelley, J-E Bach, and W. Savino. 1991. 
Identification and functional activity of prolactin receptors in 
thymic epithelial cells. Pro~ Natl. Acad. Sci. USA.  88:9700. 
14.  Frantz,  A.G. 1978. Prolactin.  N. Engl. f  Med. 298:201. 
15.  McMurray,  R.,  D.  Keisler, K.  Kanuckel, S.  Izui,  and S.E. 
Walker. 1991. Prolactin influences autoimmune disease activity 
in the female B/W mouse. J. Immunol. 147:3780. 
236  Neuroendocrine  Hormones and T Cell Function 